GLP-1
-
Wegovy Weight Loss Drug Sees Major 30% Price Cut as Pharma Giants Respond to Pressure
Novo Nordisk has slashed Wegovy’s price by 30%, a move hailed as transformative for patient access. The decision follows mounting pressure from the Trump Administration to make weight loss and diabetes treatments more affordable.
-
Semaglutide Shows Promise in Treating Liver Disease MASH
A landmark phase 3 trial reveals semaglutide’s potential to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions globally.
-
Decoding Satiety: Unlocking the Brain’s Appetite Control Mechanism
New Research Identifies Key Neurons That Signal When to Stop Eating, Offering Potential for Obesity Treatment We’ve all experienced that moment when we realize we’ve had enough to eat. But how does our brain know when to stop? Groundbreaking research…
-
Medicare Drug Price Negotiations to Continue, with Focus on Transparency
The Centers for Medicare & Medicaid Services (CMS) has announced it will proceed with Medicare drug price negotiations under the current administration, emphasizing a commitment to greater transparency in the process. This second round of negotiations will include high-profile, expensive…